Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.

Share this video  

ASH 2015 | Overview of a promising new study of venetoclax in patients with CLL

Jacqueline Barrientos • 6 Jan 2016
ASH 2015
Chronic Lymphocytic Leukemia Venetoclax

Jacqueline Barrientos, MD, from the North Shore-Long Island Jewish Health System in New York, discusses a promising new study of the anti-apopotopic (Bcl-2 inhibitor) venetoclax in patients with CLL. Early data suggest that this may achieve minimum residual disease (MRD) negativity with a low risk of side effects.

More from Jacqueline Barrientos

Fixed-duration versus continuous treatment of venetoclax-based regimens in CLL 5:35
Fixed-duration versus continuous treatment of venetoclax-based regimens in CLL
Jacqueline Barrientos • 19 Jun 2025
Promising agents in the treatment of CLL: BTK degraders and novel BCL2 inhibitors 2:18
Promising agents in the treatment of CLL: BTK degraders and novel BCL2 inhibitors
Jacqueline Barrientos • 19 Jun 2025
Understanding mechanisms of resistance to BTK and BCL2 inhibitors in patients with CLL 3:47
Understanding mechanisms of resistance to BTK and BCL2 inhibitors in patients with CLL
Jacqueline Barrientos • 19 Jun 2025
Uptake of targeted agents by race/ethnicity in patients receiving first-line treatment for CLL 11:33
Uptake of targeted agents by race/ethnicity in patients receiving first-line treatment for CLL
Jacqueline Barrientos • 19 Jun 2025

Related Videos

Practice-changing abstracts from ASH 2025 for community oncologists treating NHL and CLL 1:28
Practice-changing abstracts from ASH 2025 for community oncologists treating NHL and CLL
Tara Graff • 8 Dec 2025
Developing and testing a tandem CD19/ROR1 CAR-NK to overcome apoptotic resistance in CLL 1:21
Developing and testing a tandem CD19/ROR1 CAR-NK to overcome apoptotic resistance in CLL
Matthew Davids • 8 Dec 2025
First-in-human Phase I results of a novel BTK inhibitor rocbrutinib in R/R CLL 2:08
First-in-human Phase I results of a novel BTK inhibitor rocbrutinib in R/R CLL
Jennifer Woyach • 8 Dec 2025
Pirtobrutinib versus ibrutinib in treatment-naïve and R/R CLL: findings from BRUIN-CLL-314 2:54
Pirtobrutinib versus ibrutinib in treatment-naïve and R/R CLL: findings from BRUIN-CLL-314
Jennifer Woyach • 8 Dec 2025
The content of VJHemOnc is intended for healthcare professionals